Docoh
Loading...

LXRX Lexicon Pharmaceuticals

News

From Benzinga Pro
21 Stocks Moving In Friday's Mid-Day Session
31 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
A Peek Into The Markets: US Stock Futures Edge Lower On Final Trading Day Of 2021
31 Dec 21
Earnings, News, Penny Stocks, Eurozone, Futures, Small Cap, Global, Pre-Market Outlook, Markets
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade on the final trading day of 2021. The Dow Jones dropped around 90 points, snapping a six-session winning streak on Thursday.
5 Stocks To Watch For December 31, 2021
31 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Trading Ideas
Some of the stocks that may grab investor focus today are: Medalist Diversified REIT, Inc. (NASDAQ: MDRR) reported a stock repurchase program of 500,000 shares. Medalist Diversified shares climbed 22.6% to $1.25 in the after-hours trading session.
12 Health Care Stocks Moving In Thursday's After-Market Session
30 Dec 21
Movers
Gainers
Lexicon Submits New Drug Application For Sotagliflozin For Treatment Of Heart Failure In Adults With Type 2 Diabetes
30 Dec 21
News, FDA
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to
12 Health Care Stocks Moving In Friday's After-Market Session
3 Dec 21
Movers
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 22.13% to $1.49 during Friday's after-market session. The market value of their outstanding shares is at $20.4 million.
Lexicon's Sotagliflozin Shows Benefits in Heart Failure, Blood Glucose Control
15 Nov 21
Biotech, News, Health Care, Small Cap, General
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Nov 21
Pre-Market Outlook, Markets, Movers
New Analysis To Be Presented At The American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function
9 Nov 21
News, Events
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association
81 Biggest Movers From Yesterday
5 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Nov 21
Pre-Market Outlook, Markets, Movers
Lexicon Pharmaceuticals Q3 EPS $(0.16) Beats $(0.18) Estimate, Sales $23.00K Down From $6.63M YoY
3 Nov 21
Earnings, News
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 62.79 percent increase over losses of $(0.43) per
Recap: Lexicon Pharmaceuticals Q3 Earnings
3 Nov 21
Earnings
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Earnings Scheduled For November 3, 2021
3 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

Press releases

From Benzinga Pro
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
4 Jan 22
News, Press Releases
THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, Lexicon's chief executive officer, will present at the 40th Annual J.P. Morgan
Thinking about buying stock in Assertio Holdings, Siyata Mobile, Insignia Systems, Energy Focus, or Lexicon Pharmaceuticals?
31 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASRT, SYTA, ISIG, EFOI, and LXRX.
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
30 Dec 21
Press Releases, General
THE WOODLANDS, Texas, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference
15 Nov 21
News, Press Releases
THE WOODLANDS, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its virtual participation in the following conferences: Jefferies London Healthcare Conference,
Lexicon's Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data
14 Nov 21
Analyst Ratings, Press Releases
Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: Sotaglifozin
New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function
9 Nov 21
Health Care, Press Releases
THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies
Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update
3 Nov 21
Earnings, Press Releases
THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key
Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021
28 Oct 21
News, Press Releases
THE WOODLANDS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close.